iron chelation therapy advances in experimental medicine iron chelation therapy rd.springer iron chelation therapy advances in experimental medicine iron chelation therapy advances in experimental medicine bioactive components of human milk advances in advances clinical science experimental medicine mycotoxins and food safety advances in experimental progress in iron research springer a world b...

Chelation therapy is the preferred medical treatment for reducing the toxic effects of metals. Chelating agents are capable of binding to toxic metal ions to form complex structures which are easily excreted from the body removing them from intracellular or extracellular spaces. 2,3-Dimercaprol has long been the mainstay of chelation therapy for lead or arsenic poisoning, however its serious si...

Heart failure secondary to iron overload is the main cause of death in patients with beta-thalassemia major. Combination therapy with deferoxamine and deferiprone has been shown to be more effective than either drug used alone in patients with beta-thalassemia major and symptomatic cardiomyopathy. Although monitoring the response to chelation therapy is usually carried out by indirect measureme...

conclusion adrenal iron in β-tm can be reliably measured in 3 tesla mri. the results highlight the absence of correlation between adrenal iron deposition both with serum ferritin and hepatic iron. results among patients, there was no significant correlation between plasma ferritin and adrenal t2*. significant difference was detected among t2* values of adrenals between the patient and control g...

background: one of the most common endocrine problems in major beta-thalassemia is hypothyroidism (ht). the aim of this study was to evaluate thyroid function status in major beta-thalassemia patients older than 10 years old. methods: this cross sectional study was carried out on thalassemia major patients registered on thalassemia center of amirkola children hospital in babol. a questionnaire ...

Chelation therapy with deferoxamine is effective in preventing the risk of transfusional iron overload, but treatment failure is common because of noncompliance. To reduce the transfusional iron load, we have evaluated longterm erythrocytapheresis in 14 subjects with sickle cell disease and stroke (11) or other complications (3) as an alternative to simple transfusion. Subjects were treated wit...

Iron overload remains a concern in MDS patients especially those requiring recurrent blood transfusions. The consequence of iron overload may be more relevant in patients with low and intermediate-1 risk MDS who may survive long enough to experience such manifestations. It is a matter of debate whether this overload has time to yield organ damage, but it is quite evident that cellular damage an...

Reports are emerging of hematologic responses associated with iron chelation therapy; however, studies are limited in aplastic anemia patients. Deferasirox reduced iron overload in aplastic anemia patients enrolled in the EPIC (Evaluation of Patients' Iron Chelation with Exjade(®)) study (n=116). A post hoc analysis of hematologic responses was conducted on 72 patients with evaluable hematologi...

Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-thalassemia (n = 274) and myelodysplastic syndrome (MDS) patients (n = 168) patients participating in the Evaluatio...

BACKGROUND Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on there reductions/improvements have been limited to case reports and small studies. DESIGN AND METHODS To explore this observation in a large population of patients, w...